ERBB2 and invasive breast carcinoma: Recent data from KATHERINE trial, among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, has shown a reduction of 50% of the risk of recurrence of invasive breast cancer or death with adjuvant T-DM1 instead of trastuzumab alone10.